Immunome (NASDAQ:IMNM) Announces Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Immunome (NASDAQ:IMNM) announced its earnings results on Tuesday. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10), FiscalAI reports. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 75.83%.

Here are the key takeaways from Immunome’s conference call:

• Varegacestat delivered striking phase III topline results (84% reduction in progression risk, HR 0.16; 56% ORR; 83% median tumor volume reduction) and Immunome plans an NDA submission in Q2 2026 with a generally manageable safety profile and intent to self-launch.
• Company says previous manufacturing issues have been resolved, with ample commercial supply capacity and a planned cost‑effective U.S. launch infrastructure (roughly the ~32–35 rep footprint comparable to the prior launch).
• Immunome’s proprietary ADC payload HC74 (Topo1) claims resistance to efflux mechanisms and enhanced bystander activity; lead ADC IM‑1021 is in dose escalation and three additional HC74 ADCs (including IM‑1617 with a strong preclinical package) are expected to file INDs in 2026, materially expanding the pipeline.
• Significant execution and translational risk remains: ADCs and the FAP radiotherapy program are early‑stage (preclinical/phase I), and expanding the desmoid market beyond the ~10% currently on gamma‑secretase inhibitors will depend on real‑world adherence, payer uptake, and successful NDA review.

Immunome Trading Up 4.5%

Shares of IMNM opened at $22.52 on Thursday. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -9.31 and a beta of 2.12. The firm’s fifty day simple moving average is $22.78 and its 200-day simple moving average is $17.58. Immunome has a twelve month low of $5.15 and a twelve month high of $27.65.

Analyst Upgrades and Downgrades

IMNM has been the topic of several research reports. Craig Hallum increased their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. Stephens reduced their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday. Truist Financial began coverage on shares of Immunome in a research report on Monday, December 1st. They issued a “buy” rating and a $36.00 price target for the company. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research note on Thursday, January 15th. Finally, Lake Street Capital increased their price objective on Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.33.

Insider Buying and Selling

In other Immunome news, insider Philip Tsai acquired 10,000 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were acquired at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the acquisition, the insider owned 43,300 shares in the company, valued at $887,217. The trade was a 30.03% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Clay B. Siegall bought 46,511 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average cost of $21.50 per share, for a total transaction of $999,986.50. Following the transaction, the chief executive officer directly owned 853,247 shares in the company, valued at approximately $18,344,810.50. This represents a 5.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders bought 68,518 shares of company stock worth $1,453,958. Corporate insiders own 7.69% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently added to or reduced their stakes in IMNM. Nisa Investment Advisors LLC raised its position in Immunome by 3,513.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 80,426 shares of the company’s stock valued at $942,000 after purchasing an additional 78,200 shares during the last quarter. Nan Fung Trinity HK Ltd. increased its stake in Immunome by 7.9% in the third quarter. Nan Fung Trinity HK Ltd. now owns 592,103 shares of the company’s stock valued at $6,934,000 after purchasing an additional 43,253 shares during the period. Kennedy Capital Management LLC increased its stake in Immunome by 642.6% in the second quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock valued at $1,017,000 after purchasing an additional 94,627 shares during the period. Tema Etfs LLC purchased a new stake in shares of Immunome in the second quarter valued at about $1,074,000. Finally, NEOS Investment Management LLC boosted its stake in shares of Immunome by 40.5% during the third quarter. NEOS Investment Management LLC now owns 162,186 shares of the company’s stock worth $1,899,000 after buying an additional 46,755 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.